These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 19632951)

  • 41. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.
    Hill A; Sawyer W
    HIV Med; 2009 Oct; 10(9):527-35. PubMed ID: 19785663
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial.
    Arribas JR; Girard PM; Landman R; Pich J; Mallolas J; Martínez-Rebollar M; Zamora FX; Estrada V; Crespo M; Podzamczer D; Portilla J; Dronda F; Iribarren JA; Domingo P; Pulido F; Montero M; Knobel H; Cabié A; Weiss L; Gatell JM;
    Lancet Infect Dis; 2015 Jul; 15(7):785-92. PubMed ID: 26062880
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of atazanavir Ctrough, atazanavir genotypic inhibitory quotient, and baseline HIV genotype as predictors of a 24-week virological response in highly drug-experienced, HIV-infected patients treated with unboosted atazanavir.
    Gianotti N; Seminari E; Guffanti M; Boeri E; Villani P; Regazzi M; Bigoloni A; Schira G; Tiberi S; Fusetti G; Lazzarin A; Castagna A
    New Microbiol; 2005 Apr; 28(2):119-25. PubMed ID: 16035256
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and safety of switching to raltegravir plus atazanavir dual therapy in pretreated HIV-1-infected patients over 144 weeks: a cohort study.
    Gantner P; Koeppel C; Partisani M; Batard ML; Bernard-Henry C; Cheneau C; De Mautort E; Priester M; Muret P; Sueur C; Fafi-Kremer S; Rey D
    Scand J Infect Dis; 2014 Dec; 46(12):838-45. PubMed ID: 25229167
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Simplified maintenance therapy with abacavir/lamivudine/zidovudine plus tenofovir after sustained HIV load suppression: four years of follow-up.
    d'Ettorre G; Zaffiri L; Ceccarelli G; Andreotti M; Massetti AP; Vella S; Mastroianni CM; Vullo V
    HIV Clin Trials; 2007; 8(3):182-8. PubMed ID: 17621465
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy.
    Belmonti S; Lombardi F; Quiros-Roldan E; Latini A; Castagna A; Borghetti A; Baldin G; Ciccullo A; Cauda R; De Luca A; Di Giambenedetto S;
    J Antimicrob Chemother; 2018 Jul; 73(7):1949-1954. PubMed ID: 29788156
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study.
    Wolbers M; Opravil M; von Wyl V; Hirschel B; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Battegay M; Yerly S; Günthard H; Bucher HC;
    AIDS; 2007 Oct; 21(16):2201-7. PubMed ID: 18090047
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Switching to lopinavir/ritonavir with or without abacavir/lamivudine in lipoatrophic patients treated with zidovudine/abacavir/lamivudine.
    Bernardino JI; Pulido F; Martinez E; Arrizabalaga J; Domingo P; Portilla J; Ocampo A; Muñoz J; Torres R; Arribas JR;
    J Antimicrob Chemother; 2013 Jun; 68(6):1373-81. PubMed ID: 23386261
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial.
    Haas DW; Zala C; Schrader S; Piliero P; Jaeger H; Nunes D; Thiry A; Schnittman S; Sension M;
    AIDS; 2003 Jun; 17(9):1339-49. PubMed ID: 12799555
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pharmacokinetics and pharmacodynamics of atazanavir-containing antiretroviral regimens, with or without ritonavir, in patients who are HIV-positive and treatment-naïve.
    Bertz RJ; Persson A; Chung E; Zhu L; Zhang J; McGrath D; Grasela D
    Pharmacotherapy; 2013 Mar; 33(3):284-94. PubMed ID: 23456732
    [TBL] [Abstract][Full Text] [Related]  

  • 51. No difference in effectiveness of treatment simplification to boosted or unboosted atazanavir plus lamivudine in virologically suppressed in HIV-1-infected patients.
    Gutierrez-Valencia A; García C; Viciana P; Milanés-Guisado Y; Fernandez-Magdaleno T; Espinosa N; Pasquau J; López-Cortés LF
    PLoS One; 2018; 13(9):e0203452. PubMed ID: 30235244
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Estimated glomerular filtration rates through 144 weeks on therapy in HIV-1-infected subjects receiving atazanavir/ritonavir and abacavir/lamivudine or simplified to unboosted atazanavir/abacavir/lamivudine.
    Young B; Squires KE; Tashima K; Henry K; Schneider S; LaMarca A; Zhao HH; Ross LL; Shaefer MS
    HIV Clin Trials; 2015 Aug; 16(4):125-9. PubMed ID: 26133089
    [No Abstract]   [Full Text] [Related]  

  • 53. Predictors of virological response to atazanavir in protease inhibitor-experienced patients.
    Barrios A; Rendón AL; Gallego O; Martín-Carbonero L; Valer L; Ríos P; Maida I; García-Benayas T; Jiménez-Nácher I; González-Lahoz J; Soriano V
    HIV Clin Trials; 2004; 5(4):201-5. PubMed ID: 15472794
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and safety of once-daily ritonavir-boosted darunavir and abacavir/lamivudine for treatment-naïve patients: a pilot study.
    Nishijima T; Tsukada K; Teruya K; Gatanaga H; Kikuchi Y; Oka S
    AIDS; 2012 Mar; 26(5):649-51. PubMed ID: 22233654
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Atazanavir/ritonavir: a review of its use in HIV therapy.
    von Hentig N
    Drugs Today (Barc); 2008 Feb; 44(2):103-32. PubMed ID: 18389089
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lipid-lowering efficacy and safety after switching to atazanavir-ritonavir-based highly active antiretroviral therapy in patients with human immunodeficiency virus.
    Nguyen ST; Eaton SA; Bain AM; Rahman AP; Payne KD; Bedimo R; Herrington JD; Maclayton DO; Rodriguez-Barradas MC; Busti AJ
    Pharmacotherapy; 2008 Mar; 28(3):323-30. PubMed ID: 18294112
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study).
    Pellegrin I; Breilh D; Ragnaud JM; Boucher S; Neau D; Fleury H; Schrive MH; Saux MC; Pellegrin JL; Lazaro E; Vray M
    Antivir Ther; 2006; 11(4):421-9. PubMed ID: 16856615
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
    Manfredi R; Calza L
    AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Short communication: lamivudine plus a boosted-protease inhibitor as simplification strategy in HIV-infected patients: proof of concept.
    Casado JL; de la Calle C; del Palacio M; Perez-Elías MJ; Moreno A; Moreno S
    AIDS Res Hum Retroviruses; 2013 Mar; 29(3):588-91. PubMed ID: 23163811
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.